Moderna plans to invest over $140m to expand its US manufacturing capabilities by onshoring drug product manufacture to its existing Moderna Technology Center in Massachusetts. This move will allow the company to operate complete end-to-end mRNA medicines manufacturing across the country, supporting commercial and clinical supply.

The initiative is part of Moderna’s ongoing investment in US-based infrastructure to establish a manufacturing platform for its mRNA therapies and vaccines. Since partnering with the US government through Operation Warp Speed, the company’s mRNA platform has made significant advancements in biomedical innovation across various health areas.

Construction of the new facility in Norwood, Massachusetts has begun, with completion expected in the first half of 2027. This investment will lead to the creation of several skilled biomanufacturing jobs. In 2025, Moderna received $590m in funding from the US Department of Health and Human Services to expedite the development of mRNA-based pandemic influenza vaccines, enhancing the country’s preparedness for future infectious diseases.

Read more at Yahoo Finance: Moderna to onshore drug product manufacturing to Massachusetts